Mark Currie
Questioner · DISC type cDr. Mark Currie is a distinguished pharmaceutical leader and Venture Partner at Iaso Ventures, holding board positions at Sea Pharmaceuticals and Ironwood Pharmaceuticals. With a Ph. D. from Wake Forest University, his career is marked by senior R&D roles where he guided the development of novel therapies from discovery to market.
Outside of his primary professional focus, Mark has expressed a keen interest in environmental science, particularly in advancing the scientific understanding of coastal waters. He actively follows and encourages the work of teams dedicated to marine and coastal research, highlighting a passion that bridges science and nature.
His pioneering academic research on the guanylate cyclase-C (GC-C) pathway laid the foundation for the discovery of the blockbuster drug linaclotide (LINZESS).
Read the full overview →How Mark shows up
They are more likely than others to negotiate on pricing and terms. While they don't hesitate to ask questions, they are generally risk-averse and tend to be late adopters. They prefer to do thorough analysis of any situation.
Topics Mark cares about
Work history
Media appearances
DISC profile (public)
Calculativeness (C)
Calculativeness (C) reflects the degree to which a person is likely to be cautious, systematic and analytical. Those scoring high tend to emphasise quality and accuracy.
More profiles
Discover additional public profiles from our index.
Search more profiles
Looking for someone else? Search here for anyone.